4 April 2016
Reflecting on his three years at the helm of the Medicines Patent Pool (MPP), executive director Greg Perry has good reason to be proud. By negotiating voluntary licences with all the major originators and intellectual-property (IP) holders in the antiretrovirals sector, the MPP has already saved healthcare authorities around the world well over US$100 million, and savings of around US$1.5 billion are anticipated up to 2028. And with a remit recently broadened to cover hepatitis C and tuberculosis treatments, the organisation is in prime position to fulfil a major public-health role.
Read full aricle here.
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.